FXR agonists in NASH treatment.

Area of Science:

• Hepatology and Gastroenterology
• Molecular Endocrinology
• Pharmacology

Background:

• Non-alcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatments.
• The farnesoid X receptor (FXR) plays a key role in regulating liver and gut functions, including metabolism and inflammation.
• FXR activation is a promising therapeutic strategy for NASH due to its pleiotropic effects.

Purpose of the Study:

• To review preclinical and clinical data of advanced farnesoid X receptor (FXR) agonists.
• To evaluate the therapeutic potential of FXR agonists in treating non-alcoholic steatohepatitis (NASH).

Main Methods:

• Literature review of preclinical studies and clinical trials involving FXR agonists.
• Classification of FXR agonists based on their chemical properties (bile acid derivatives, steroidal, non-steroidal, partial agonists).
• Critical evaluation of the efficacy and safety profiles of advanced FXR agonists.

Main Results:

• Several FXR agonists, including bile acid derivatives and non-steroidal compounds, are in advanced clinical development.
• These agonists target key pathways involved in NASH pathogenesis, such as steatosis, inflammation, and fibrosis.
• Early clinical data suggest potential efficacy, but further investigation is ongoing.

Conclusions:

• FXR agonists represent a significant therapeutic opportunity for NASH.
• Different classes of FXR agonists offer varied pharmacological profiles for NASH treatment.
• Continued research and clinical trials are essential to establish the role of FXR agonists in NASH management.